# Olanzapine Impact on First-line Immunotherapy for Advanced EGFR-negative NSCLC

> **NCT06554613** · PHASE2 · RECRUITING · sponsor: **Second Affiliated Hospital of Nanchang University** · enrollment: 156 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Olanzapine
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT06554613
- **Lead sponsor:** Second Affiliated Hospital of Nanchang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-02
- **Primary completion:** 2026-12-01
- **Final completion:** 2027-05-31
- **Target enrollment:** 156 (ESTIMATED)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06554613

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06554613, "Olanzapine Impact on First-line Immunotherapy for Advanced EGFR-negative NSCLC". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06554613. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*